A shot in the dark at the behest of a red herring

The announcement on 12 October by Eli Lilly that it has terminated its Phase 3 clinical trial of evacetrapib ACCELERATE on the grounds of lack of efficacy has not surprised those of us who have harboured serious doubts about the concept of CETP inhibition since it arose more than 20 years ago. While the value […]

Cholesteryl ester transport protein inhibitors

Some of you may have read my recent article on CETP inhibitors and cardiovascular disease in Frontiers in Pharmacology, which updated my review on the same theme published in F1000Research twelve months ago. I know that my call for action in relation to the two ongoing clinical trials is not shared by everyone, but having received letters of support […]

Registered in England and Wales: number 6501919
VAT registration number: 945 1575 08
Website copyright © Oxford Pharmassist Ltd 2015
web design london : pedalo limited